A comparative study of concurrent chemoradiotherapy with cisplatin versus nedaplatin for patients with middle-advanced stage uterine cervical cancer
10.3781/j.issn.1000-7431.2011.07.017
- Author:
Xiao-Wei CHENG
1
Author Information
1. Department of Gynecologic Oncology
- Publication Type:Journal Article
- Keywords:
Cisplatin;
Concurrent chemoradiotherapy;
Nedaplatin;
Uterine cervical neoplasms
- From:
Tumor
2011;31(7):662-664
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the efficacy and adverse reactions of concurrent chemoradiotherapy with cisplatin versus nedaplatin for patients with middle-advanced stage uterine cervical cancer. Methods: Sixty-four patients with middle-advanced stage uterine cervical cancer were randomized into concurrent chemoradiotherapy with cisplatin group (n =32) and concurrent chemoradiotherapy with nedaplatin group (n =32). The short- and long-term efficacy and the adverse reactions were observed. Results: The short-term response rate between the concurrent chemoradiotherapy with cisplatin group (96.9%) and the concurrent chemoradiotherapy with nedaplatin group (100.0%) was not significantly different (P >0.05). There were no statistically significant differences in the three-year survival (71.88% vs 70.97%), local recurrence rate (12.50% vs 12.90%) and distant metastasis rate (6.25% vs 6.45%) between these two groups (P >0.05). The incidences of gastrointestinal toxicity and renal dysfunction in the concurrent chemoradiotherapy with cisplatin group were higher than those in the concurrent chemoradiotherapy with nedaplatin (P <0.05), while the incidence of thrombopenia was lower in the concurrent chemoradiotherapy with cisplatin group (P <0.05). Conclusion: Concurrent chemoradiotherapy with cisplatin/ nedaplatin can improve the short- and long-term efficacy and reduce the local recurrence and distant metastasis of patients with middle-advanced stage uterine cervical cancer. These two treatment regimens are both well-tolerated. Copyright© 2011 by TUMOR.
